Isis Pharmaceuticals, Inc.

What Isis Pharmaceuticals, Inc. does

Ionis Pharmaceuticals, Inc. is a Carlsbad, California-based biopharmaceutical company founded in 1989 that pioneers RNA- and DNA-targeted antisense medicines for serious diseases. The company's core technology platform leverages antisense RNA-targeted chemistry to precisely address disease-causing genetic sequences, supported by what the company describes as an industry-leading chemistry platform. Ionis (Nasdaq: IONS) operates a dual commercialization model: in the United States, the company directly commercializes its medicines following regulatory approval — as demonstrated by its first independent commercial launch, TRYNGOLZA® (olezarsen), approved by the FDA on June 24, 2026 as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG). For international markets, Ionis out-licenses commercialization rights to established partners — most recently to Recordati for zilganersen in Alexander disease (AxD) across all ex-U.S. countries, announced June 25, 2026.

The company's revenue model combines direct pharmaceutical product sales (U.S. commercialization of proprietary medicines such as TRYNGOLZA) with licensing and royalty income from out-licensed international rights and historical collaboration agreements. Its patient population targets serious, high-unmet-need conditions including severe hypertriglyceridemia, familial chylomicronemia syndrome (FCS), and rare neurological disorders such as Alexander disease. Ionis maintains a wholly-owned subsidiary, Akcea Therapeutics, focused on rare disease therapeutics. The company is led by CEO Brett Monia and recently expanded its Board of Directors with the June 2026 appointment of Ludwig Hantson, Ph.D.

Name

Isis Pharmaceuticals, Inc.

Legal name

Ionis Pharmaceuticals, Inc.

Website

https://isisph.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

251–500 employees

Short description

Ionis Pharmaceuticals is a Carlsbad, California-based biopharmaceutical company pioneering RNA-targeted antisense medicines for serious diseases, with FDA-approved TRYNGOLZA for severe hypertriglyceridemia and a development pipeline including zilganersen for Alexander disease.

Ownership category

akta.pro rank

Product category

RNA-Targeted Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• RNA-targeted therapeutics
• Antisense oligonucleotide drugs
• Biopharmaceutical medicines
• Rare disease therapeutics
• Cardiometabolic disorder treatments

Headquarters

HQ city

Carlsbad

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical product sales: Direct commercialization of proprietary medicines including TRYNGOLZA (olezarsen) for severe hypertriglyceridemia and other pipeline medicines. Ionis independently commercializes products in the U.S. market following FDA approvals.
2. Licensing and royalty revenue: Out-licensing of products to international partners such as Recordati for commercialization outside the U.S. Ionis receives licensing fees and potentially royalties from such arrangements.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Ionis Pharmaceuticals is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes RNA- and DNA-targeted antisense medicines for serious diseases. The company's lead commercial product is TRYNGOLZA (olezarsen), the first FDA-approved treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia. The pipeline also includes zilganersen for Alexander disease, being advanced with partner Recordati outside the U.S.

Product overview

Ionis Pharmaceuticals is a biopharmaceutical company pioneering RNA- and DNA-targeted medicines for serious diseases. The company's commercial portfolio includes TRYNGOLZA® (olezarsen), an FDA-approved treatment for severe hypertriglyceridemia that reduces triglycerides and acute pancreatitis risk. Zilganersen, an investigational medicine for Alexander disease, is being advanced through a license agreement with Recordati for ex-U.S. markets while Ionis retains U.S. commercialization rights. Ionis leverages industry-leading chemistry and genetic-based science to develop transformative medicines across cardiometabolic disorders and neurological conditions.

Differentiator

Problem solved

Functional benefit

Brands

• TRYNGOLZA: Brand name for olezarsen, FDA-approved treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG).
• Ion-ARPA Initiative

Products and services

• TRYNGOLZA (olezarsen) FDA-approved RNA-targeted antisense medicine for the treatment of severe hypertriglyceridemia (sHTG) in adult patients. It is the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in this patient population.
• Zilganersen Investigational RNA-targeted antisense medicine in development for Alexander disease (AxD), a rare neurological disorder. Licensed to Recordati for commercialization outside the U.S.; Ionis retains U.S. commercialization rights pending FDA approval.

Quantifiable outcome

• TRYNGOLZA (olezarsen) approved by FDA as first and only treatment to reduce triglycerides and risk of acute pancreatitis in patients with severe hypertriglyceridemia

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• RecordaticoreOEM/ Whitelabel/ Licensing Partner · 25 June 2026Ionis announced a license agreement with Recordati for zilganersen in Alexander disease (AxD) for all countries outside the U.S. Recordati brings deep rare disease expertise and proven capabilities in commercialization, access, and country-specific regulatory environments. Ionis will independently commercialize zilganersen in the U.S. assuming FDA approval. This partnership leverages Recordati's established international infrastructure for rare disease commercialization.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Alnylam Pharmaceuticals: Alnylam is the leading RNAi (RNA interference) therapeutics company, directly comparable to Ionis as both companies develop RNA-targeted medicines using oligonucleotide-based platforms to address serious genetic diseases. Both leverage proprietary chemistry and pursue similar therapeutic areas including cardiometabolic and rare diseases.
• Sarepta Therapeutics: Sarepta develops RNA-targeted therapies, including antisense oligonucleotides and gene therapies, for rare neuromuscular diseases. Sarepta is directly comparable to Ionis as both companies pioneered RNA-targeting approaches for serious genetic disorders and have transitioned to commercial-stage biopharmaceutical companies.
• Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics using its proprietary TRiM platform targeting RNA, closely paralleling Ionis' antisense approach. Both companies focus on serious diseases including cardiometabolic and rare genetic conditions, with multiple partnered programs.

Emerging players

• Wave Life Sciences: Wave Life Sciences is a clinical-stage genetic medicines company developing stereopure antisense oligonucleotides, directly competing with Ionis' antisense platform in similar therapeutic areas including neurological and rare diseases.
• Dyne Therapeutics: Dyne Therapeutics develops RNA-targeted therapies for serious muscle diseases, sharing Ionis' approach of leveraging oligonucleotide chemistry to address genetic diseases. While smaller and more focused, Dyne represents the next generation of RNA-targeted therapeutic companies.
• Stoke Therapeutics: Stoke Therapeutics develops antisense oligonucleotide medicines that increase protein production by targeting RNA splicing, addressing genetic diseases including severe neurological conditions — directly comparable to Ionis' approach for Alexander disease and similar indications.
• BridgeBio Pharma: BridgeBio is a commercial-stage biopharmaceutical company focused on genetic diseases and conditions with clear genetic drivers, paralleling Ionis' genetics-based approach. Both companies target serious diseases with significant unmet need across cardiometabolic and rare disease areas.
• Moderna: Moderna is an RNA-focused biotechnology company that, while primarily known for mRNA vaccines, is expanding into RNA-targeted therapeutics. Moderna represents an adjacent RNA platform competitor that could compete with Ionis in RNA-targeted medicine development.

Broad incumbents

• Biogen: Biogen is an established biopharmaceutical company focused on neurological and rare diseases, overlapping with Ionis' neurology pipeline (Alexander disease, FCS). As a broader incumbent, Biogen has the commercial infrastructure and global reach that Ionis is building.
• Regeneron Pharmaceuticals: Regeneron is a large biopharmaceutical company with a deep pipeline in cardiometabolic, ophthalmology, and rare diseases, overlapping with Ionis' therapeutic focus areas. As a broader incumbent, Regeneron offers established commercial and R&D scale that contrasts with Ionis' platform-focused approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ionispharma
• Facebookfacebook.com/ionispharma
• LinkedInlinkedin.com/company/ionis-pharmaceuticals
• Instagraminstagram.com/ionis_pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Isis Pharmaceuticals, Inc.